Coronavirus information from UCLA and UCLA Health.


The Next Generation Incubator

Orchard Therapeutics is targeting disorders with no treatment option or where existing options leave significant management gaps. Orchard’s autologous ex vivo gene therapy uses a patient’s own blood stem cells to correct a genetic disorder. Stem cells are taken from the patient (step 1) and modified outside of the body (“ex vivo”) using a viral vector carrying a functioning copy of the missing or faulty gene (step 2). The gene-modified cells are then transplanted back into the body (step 3).
In April 2018, Orchard Therapeutics raised Series C financing and acquired GSK's rare disease portfolio through a strategic agreement. This acquisition strengthens Orchard's position as a global leader in gene therapy for rare diseases. Read more about it here!

Graduated in 2017
Location: Headquartered in London, UK with offices in Boston, Foster City, and Menlo Park